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The design and fabrication of sustained/controlled release dosage forms, employing new excipients capable of extending/con-
trolling the release of drugs from the dosage forms over prolonged periods, has worked well in achieving optimally enhanced
therapeutic levels of the drugs. In this sense, the objective of this study was to investigate the suitability of selected cellulose ether
derivatives for use in direct compression (DC) and as eﬃcient drug release controlling agents. Controlled release matrix tablets
of ciproﬂoxacin were prepared at diﬀerent drug-to-polymer (D:P) ratios by direct compression using a ﬁne particle sized
ethylcellulose ether derivative (ETHOCEL Standard Premium 7FP) as rate controlling polymer. The tablets obtained were
evaluated for various physico-chemical characteristics and in-vitro drug release studies were conducted in phosphate buﬀer (pH
7.4)usingPharmaTestdissolutionapparatusatconstanttemperatureof37
◦C±0.1.Similarityfactor f2 wasemployedtotherelease
proﬁles of test formulations and were compared with marketed ciproﬂoxacin conventional tablets. Drug release mechanism and
the kinetics involved were investigated by ﬁtting the release proﬁle data to various kinetic models. It was found that with increasing
the proportion of ethylcellulose ether derivative in the matrix, the drug release was signiﬁcantly extended up to 24 hours. The
tablets exhibited zero order or nearly zero order drug transport mechanism. In vivo drug release performance of the developed
controlledreleasetabletsandreferenceconventionaltabletscontainingciproﬂoxacinweredeterminedinrabbitserumaccordingto
randomized two-way crossover study design using High Performance Liquid Chromatography. Several bioavailability parameters
of both the test tablets and conventional tablets including Cmax, Tmax and AUC0-t were compared which showed an optimized Cmax
and Tmax (P<0.05). A good correlation was obtained between in vitro drug release and in vivo drug absorption with correlation
value(R2 = 0.934).Relativebioavailabilitywasfoundtobe93%.Reproducibilityofmanufacturingprocessandacceleratedstability
of the developed tablets were performed in stability chamber at 40 ± 2◦Ca n d7 5± 5% relative humidity for a period of 6 months
and were found to be stable throughout the stability period.
1.Introduction
In the current years of development in the ﬁeld of pharma-
ceutics, the administration of drugs in a new challenging and
controlled approach is being given great attention for im-
proved therapeutic levels. Various controlled release dosage
forms have been developed or under development in order
to achieve this approach in treating various kinds of diseases
because of their improved results and advantages over the
conventional dosage forms [1].Anidealdrugdeliverysystem
should have two basic properties, the ﬁrst is the delivery of
drug according to the need of the body over a period of treat-
ment, and the second is targeted delivery to the site of action.
These properties can be achieved by controlled release drug
delivery systems which can improve the therapeutic eﬀect
and safety of a drug inside the body by reducing the dosage
frequency. Furthermore, the need of cheap medicaments has
been generating interest in controlled release drug delivery
systems[2].Variousconventionalandcontrolledreleasedos-
age forms with diﬀerent doses have been formulated, and
from investigations it is cleared that there is no diﬀerence be-
tween the conventional dosage forms given several times a2 The Scientiﬁc World Journal
day and controlled release dosage form given once a day with
respect to bioavailability and therapeutic eﬀects [2].
Drug release is controlled by a combination of several
physical processes like diﬀusion, polymer swallowing, ero-
sion, and dissolution. Swellability of the polymer controls
primarily the dissolution and diﬀusion of the drug by pen-
etration of the water through the tablet. The polymer swella-
bility, erosion control, and the drug release rate, all depend
on the molecular weight of the polymer, degree of substitu-
tion, and the polymer concentration [1].
Ciproﬂoxacin is most widely used in UTI’s with a good
localized action on the infected sites. Ciproﬂoxacin produces
high urine concentrations because about 50% is excreted in
urine in unchanged form [3]. It belongs to quinolones which
have broad spectrum activity against many types of gram-
positive as well as gram-negative bacteria to control various
diseases.
Previouslywehaveworkedonthedevelopment andeval-
uation of controlled release drug delivery matrices based on
diﬀerent grades and types of polymers [4]. In this paper we
have explored design controlled release (CR) matrix tablets
of ciproﬂoxacin HCl testing a ﬁne particle sized ethyl cellu-
lose ether derivative (ETHOCEL Standard Premium 7FP) at
diﬀerent drug-to-polymer (D:P) ratios and the main focus
of this study was to investigate inﬂuence of diﬀerent concen-
tration of the polymer and coexcipients on the release rate
and mechanism from controlled release tablets.
2.MaterialsandMethods
NaOH(Merck,Germany),monobasicpotassiumphosphate,
ciproﬂoxacinHCl(VelourPharmaIslamabad,Pakistan),lac-
tose and magnesium stearate (BDH chemical limited, Pool
England),ETHOCEL7P(DowChemicalCo.,MidlandUSA),
acetonitrile HPLC grade (Malinckrodt, USA), methanol
(BDH, UK), pentane, dichloromethane (Malinckrodt, USA),
ciproxin conventional tabs by Bayar Pharma containing
250mg ciproﬂoxacin, HPLC (Perkin Elmer Series 200, USA)
Pharma Test Dissolution Apparatus (D-63512, Hainburg),
Single Punch Tablet machine (Erweka AR 400, Germany),
UV-visible spectrophotometer (UVIDEC-1601 Shimadzu,
Japan), friability tester (Erweka TA3R, Germany) and hard-
ness tester (Erweka Apparatus TB24, Germany).
2.1. Preparation of Matrix Tablets
2.1.1. Tablet Formulations. Controlled release tablets of ci-
proﬂoxacin HCl were formulated for the direct compression
method using ETHOCEL 7P polymer at drug-to-polymer
ratios of 10:1, 10:2, 10:3, 10:4, 10:5, 10:6, 10:7, and
10:8 as shown in the Table 1. Lactose was used as ﬁller and
magnesium stearate (0.5%) was used as lubricant.
2.1.2. Tablet Compression. For each formulation, a weighed
amount of ciproﬂoxacin HCl along with other excipients was
taken and was blended geometrically with the help of pestle
and mortar. This mixture was passed through mesh # 8 for
three repeated times and a weighed amount of lubricant
Table 1: Formulation of 200mg ciproﬂoxacin HCl tablets.
Drug D:P ratio Polymer Filler (lactose) Lubricant (0.5%)
Ciproﬂoxacin HCl-ETHOCEL CR tablets
100mg 10:01 10mg 89mg 1mg
100mg 10:02 20mg 79mg 1mg
100mg 10:03 30mg 69mg 1mg
100mg 10:04 40mg 59mg 1mg
100mg 10:05 50mg 49mg 1mg
100mg 10:06 60mg 39mg 1mg
100mg 10:07 70mg 29mg 1mg
100mg 10:08 80mg 19mg 1mg
(Magnesium stearate) was added and was again passed
through the same mesh for three repeated times. The mix
powder was directly compressed to core tablets each weigh-
ing 200mg by using single punch machine (Erweka AR 400,
Germany) using a compaction pressure of 7-8kg/cm2.
2.2. Physicochemical Evaluation of CR Tablets of Ciproﬂoxacin
HCl. Ciproﬂoxacin HCl directly compressed controlled
release tablets were evaluated for various physicochemical
tests including weight variation, friability, hardness, diame-
ter, and drug content. The average weight of ciproﬂoxacin
HCl tablets were calculated from 20 tablets with the help of
digitalweighingbalance.Thehardnesstestwasperformedon
10 tablets by using hardness tester (Erweka Apparatus TB24,
Germany) and average weight was determined. Friability
tests were performed on 20 tablets with the help of friability
tester (Erweka TA3R, Germany) at 25rpm for 4min and av-
eragelosswascalculated.Theaveragediameterandthickness
wasdeterminedbycheckingthediameterandthicknessof10
tablets by Vernier caliper. For drug content uniformity tests,
5 tablets were randomly collected, pulverized, and weight
equivalent to 60mg ciproﬂoxacin was extracted by using
100mL phosphate buﬀer pH 7.4 and was ﬁltered through
membrane ﬁlter. The aliquot of ﬁltered solution was diluted
was further diluted with phosphate buﬀer pH 7.4 and were
analyzed through UV-visible spectrophotometer at 271nm.
The experiment was performed in triplicate and the average
was calculated [5].
2.3. In Vitro Dissolution Studies Protocol. To investigate the
release patterns of ciproﬂoxacin HCl, in vitro dissolution
studies were performed in phosphate buﬀer pH 7.4 using
Pharma test dissolution apparatus (D-63512, Hainburg).
The USP method-I (rotting basket method) was adopted for
dissolution studies of ciproﬂoxacin HCl. One compressed
ciproﬂoxacin HCl 200mg tablet was added to each station of
dissolutionapparatuscontaining900mLdissolutionsolvent.
The temperature of the solvent was kept constant at 37◦C ±
0.1 and the rotating speed was kept constant at 100rpm.
At predetermined time intervals samples of 5mL each were
withdrawn from the dissolution solvent of each station with
the help of special collecting syringe and the dissolution sol-
ventwasimmediatelyreplacedbyfreshsolventalreadystored
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membraneﬁlter(0.45µm)toﬁlteranymacroparticlepresent
in the sample. Three replicates of every sample were analyzed
for drug concentration using UV-visible spectrophotometer
at 271nm of detection wave length and percentage releases
were calculated.
2.4. In Vitro Drug Release Kinetics. The in vitro drug release
mechanism of ciproﬂoxacin HCl from polymeric tablets in
phosphate buﬀer pH 7.4 can be described by ﬁtting the dis-
solution data in ﬁve diﬀerent kinetic models as given below.
Zero-order kinetics:
W = K1t (1)
(see [6]).
First-order kinetics:
In(100 − W) = ln100 −K2t (2)
(see [6]).
Higuchi kinetics:
W = K4t1/2 (3)
(see [7]).
Hixson-Crowell kinetics:
(100 −W)
1/3 = 1001/3 −K3t (4)
(see [6]).
Korsmeyer-Peppas kinetics:
Mt
M∞
= K5tn (5)
(see [8]).
In Korsmeyer-Peppas kinetic model an (n)v a l u ew h i c h
is a diﬀusional exponent represents the mechanism of drug
release from matrix tablets. When n = 0.5 then drug diﬀuses
withaquasi-Fickiandiﬀusionmechanismfromamatrixtab-
let. When the value of n>0.5 then anomalous or non-
Fickian diﬀusion mechanism of drug occurs and when n = 1
then non-Fickian, zero-order or case-II release kinetics oc-
curs.
2.5. Stability and Reproducibility Study. In order to deter-
mine the reproducibility of the manufacturing process, three
diﬀerent batches of selected formulations from the test were
prepared at three diﬀerent periods. Tablets were packed in
tightly air-closed high-density polyethylene jars and a proper
accelerated storage conditions was maintained, that is, 40 ±
2◦Ct e m p e r a t u r ea n d7 5± 5% relative humidity (RH) using
a stability chamber (Ti-Sc-THH-07-0400 Faisalabad, Pak-
istan). These storage conditions were in accordance with
international commission for harmonization guidelines for
a 6-month period. After the due time these tablets were eval-
uated for several physicochemical parameters including ap-
pearance, hardness, friability, and percent drug content be-
fore storage (0 time) and after storage for 1, 2, 4, and 6
months [9].
2.6. In Vivo Study Protocol. The in vivo study in rabbits was
approved by the Ethical Committee of Gomal University,
Dera Ismail Khan (KPK), Pakistan. For in vivo study cipro-
ﬂoxacin HCl-ETHOCEL CR tablets, an optimized formula-
tion prepared at D:P ratio 10:3 was selected. For in vivo
study,10healthyHimalayanangorarabbitswereselectedand
the study calculations were done according to a randomized
two-way crossover design. The selected rabbits were having
average weight of 2 ± 0.3kg. These 10 rabbits were divided
into two groups (Group A and Group B) each group having
5 rabbits and the study was conducted for two trial periods
each having one-week duration.
As shown in Table 2,i nP e r i o dIt h er a b b i t so fG r o u pA
were given the tablet from the test formulation and Group B
was given ciproﬂoxacin conventional tablet with trade name
of ciproxin by Bayar Pharma as reference standard formula-
tion. Similarly in Period II the rabbits of Group A were given
the reference standard formulation and Group B were given
the tablets from the test. Each preparation was administered
to the rabbits in the morning at 8.00 a.m. after a 24hr fast.
The tablets were introduced into the base of rabbits tongue
for ingestion through a plastic needle followed by a few
droughts of water nearly 15mL.
Throughoutthestudyperiodtherabbitswerehavingfree
excesstowaterbutwerekeptfastedfor12hrsafterthedosage
administration. At speciﬁc time intervals blood samples,
each 0.7mL, were collected from the marginal ear vein of
e a c hr a b b i ta n ds t o r e di ns m a l l3m Lt u b e sa n dw e r ea l l o w e d
to clot. In another 3mL glass tube, a 200µL serum was taken
and centrifuged at 3000rpm for 10min and the plasma from
each tube was transferred to new tubes and was kept in
refrigerators at −20◦C for further studies [10].
2.7. HPLC Analysis of Plasma Ciproﬂoxacin HCl Concentra-
tion. A reversed-phase high-performance liquid chromato-
graphic method was used for the quantitative analysis of ci-
proﬂoxacin HCl in rabbit blood plasma. This system was
comprised of HPLC (Perkin Elmer Series 200, USA) having a
TCNav software for operation. This HPLC consists of binary
pump solvent delivery system, a UV-visible wavelength de-
tector,andintegratorNCI900.Thechromatographicsepara-
tion was carried out on partition (5µmp o r es i z e ) ,4 . 0m m×
250mm ODS Hypersil C18 stainless steel analytical column
ﬁtted with a reﬁllable guard column. The detector was oper-
atedat271nmwavelength.ThemobilephaseforHPLCanal-
ysis comprised 75mM phosphate buﬀer, methanol, and ace-
tonitrile (ratio 48:26:26v/v). The plasma analysis was done
at a ﬂow rate of 1.0mL/min and quantiﬁcation was done by
heightofpeak.Inordertoquantifytheplasmaconcentration
of ciproﬂoxacin HCl from the regression equation, the peak
height ratio of ciproﬂoxacin HCl was determined.4 The Scientiﬁc World Journal
Table 2: In vivo drug dosing schedule of rabbits for a two week
period.
Group Period
II I
A Test formulation Ref: Ciproxin tabs
B Ref: Ciproxin tabs Test formulation
Prior to administration of injection, the plasma samples
were treated to extract ciproﬂoxacin HCl by the following
procedure: Plasma sample (100µL) was taken in a glass tube
with a screw cap usually made of teﬂon followed by the addi-
tion of 100µL of 1M sodium hydroxide and 6mL mixture of
pentane and dichloromethane (ratio 85:15). This mixture
was vortexed for 1-2min with the help of vortex mixture and
then was centrifuged for 10min at 3000rpm. In centrifuga-
tion,anupperorganiclayerwasseparatedwhichwastakenin
areactivialandthesolventwasevaporateduntilthecomplete
dryness of extract under a gentle stream of nitrogen at a
constant temperature of 40◦C. The ﬁnal residue was taken in
a glass tube and was reconstituted with 100µL of acetonitrile
and mixed for 1min by vortex mixture, and a 50µL of this
reconstituted solution was injected into the HPLC column
with the help of syringe. For the percentage recovery of
ciproﬂoxacin HCl, linearity, precision, and accuracy of the
method, blank plasma was taken and spiked with a known
amount of ciproﬂoxacin HCl to give concentrations of 5, 10,
20, 40, 80, and 160ng/mL and ﬁxed concentrations of cipro-
ﬂoxacin stock solution (5, 10, 20, 40, 80, and 160ng/mL).
2.8. Analysis of Pharmacokinetic Parameters. Three diﬀerent
pharmacokinetic parameters including plasma concentra-
tiontimecurve(AUC0-∞),peakplasmaconcentration(Cmax),
and time to reach peak plasma concentration (Tmax)w e r e
estimated from the plasma concentration-time proﬁle of in-
dividual rabbit serum in which Cmax and Tmax were calculat-
ed directly from the arithmetic plot of blood plasma concen-
tration of ciproﬂoxacin HCl versus time proﬁle of individual
rabbit serum and AUC0-∞ was estimated by trapezoidal rule.
The elimination rate constant Ke was determined from the
terminal slope of individual plasma concentration versus
time curve after the logarithmic transformation of plasma
concentration values and application of linear regression
[11]. Similarly, the apparent volume of distribution (Vd/f)
wascalculatedbytheequation:Dose/(AUC0-∞×Ke)whilethe
elimination half-life (t1/2) was calculated from the quotient
ln2/Ke. For the determination of individual absorption pro-
ﬁle the following equation was used:
%a b s o r b e da tt i m et = Ct +
KeAUC0-t
KeAUC0-∞
, (6)
where Ct is plasma concentration at time t, Ke is the elim-
ination rate constant, AUC0-t is the area under the plasma
concentration time curve from any time zero to time t,a n d
AUC0-∞ is the total area under the plasma concentration
versus time curve.
2.9. Statistical Analysis. A statistical procedure, analysis of
variance(ANOVA),wasusedtocalculatethevaluesofcertain
pharmacokinetic parameters such as AUC0-∞, Cmax, t1/2, Ke,
and Vd/f obtained with the two preparations. This proce-
dure has a distinguished eﬀect due to subjects, treatments,
and periods. The tmax values of the two preparations were
analyzed using the wilcoxon signed rank test for paired sam-
ples. Hence, a statistically signiﬁcant diﬀerence was consid-
ered when P<0.05.
2.10. Relative Bioavailability and In Vivo-In Vitro Correlation.
The following formula was used to calculate the percent rel-
ative bioavailability of the formulations from the test:
Percent relative bioavailability =
AUC0-t (test)
AUC0-t (reference)
×100.
(7)
For in vivo-in vitro correlation, an optimized formulation
(10:3) was selected and investigated by plotting Pa (percent
drug absorbed) against Pr (percent drug released). Wagner-
Nelson method [12] was used to calculate percent drug ab-
sorbed values while the in vitro drug release data was used to
calculate percent drug released data [9].
3. Results
The present study was conducted to formulate and evaluate
controlled release drug delivery system for ciproﬂoxacin HCl
using ETHOCEL 7P as matrix material. The results of differ-
ent physicochemical parameters applied to CR formulations
of ciproﬂoxacin HCl could be seen in Table 3. These param-
eters were evaluated to assess the quality of tablets and also
serve as a pointer to good manufacturing practices (GMP).
The tablets were having good smooth surfaces and elegant
in appearance. Weight is compendial standard to assess the
quality of tablets, in case of ciproﬂoxacin HCl controlled re-
lease matrix tablets the weight variation ranges between
199.8mg to 203.2mg which was in USP acceptable range
(>0.5%) which indicate good uniformity of weight (5). The
hardness of the tablets was in the range from 6.4 ± 0.12 to
7.1 ± 0.18 which was within acceptable range (5–10kg/cm2).
The thickness of the CR tablets was not more than 2.8 ±
0.08mm which were in range (2–4mm). The diameter of all
the tablets was 8 ± 0.07mm which was also with in USP
acceptable limits (4–13mm). The loss of weight of tablets
ranges from 0.27 ± 0.09% to 0.39 ± 0.22% which was in
limits (<0.8%). The drug content of CR tablets of all the
formulations ranges from 97.5 to 99.1 which shows a good
content uniformity of drug.
3.1. In Vitro Drug Dissolution and Kinetics. Figure 1 shows
the in vitro drug release proﬁles of ciproﬂoxacin HCl from
polymeric tablets prepared at eight diﬀerent drug-to-poly-
mer ratios with respect to time. In all the developed formu-
lations, the formulation prepared at D:P ratio of 10:3 gave
the expected result by releasing about 99% drug in 24hrs. It
could be mentionable that the hardness of the tablets did not
signiﬁcantly aﬀect the drug release rates.The Scientiﬁc World Journal 5
Table 3: Values of physicochemical parameters applied to CR tablets of ciproﬂoxacin HCl.
S/no. Parameter 10:1 10:2 10:3 10:4 10:5 10:6 10:7 10:8
(1) Weight variation (mg) 202.3 201.7 199.8 202.4 200.9 201.3 203.4 203.2
(2) Friability (%) 0.31±0.17 0.38±0.21 0.34±0.19 0.27±0.09 0.39±0.22 0.22±0.07 0.17±0.04 0.38±0.21
(3) Hardness (kg/cm2)6 .7 ±0.13 6.4 ±0.12 6.9 ±0.16 6.8 ±0.15 7.1 ±0.18 6.9 ±0.13 7.0 ±0.17 6.8 ±0.15
(4) Diameter (mm) 8 ±0.07 8 ±0.05 8 ±0.07 8 ±0.07 8 ±0.04 8 ± 0.06 8 ±0.08 8 ± 0.07
(5) Thickness (mm) 2.7 ±0.09 2.7 ±0.09 2.8 ±0.08 2.6 ±0.05 2.6 ±0.06 2.7 ±0.08 2.7 ±0.06 2.5 ±0.05
(6) Drug content (%) 98.3 97.8 102.1 97.5 98.9 101.3 99.5 98.7
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Figure 1: In vitro release proﬁles of ciproﬂoxacin HCl controlled
release tablets prepared at diﬀerent D:P ratios in phosphate buﬀer
pH 7.4 (mean ± SEM, n = 6).
Zero-order kinetic model was found to best describe the
R2 (coeﬃcient of determination). Korsmeyer-Peppas equa-
tion also best suits the dissolution data where the values of
“n”w e r e>0.9 indicating anomalous, non-Fickian, or nearly
zero-order release mechanism [13].
3.2. Stability and Reproducibility of Manufacturing Process.
The formulation with good dissolution proﬁle, that is, pre-
pared at D:P ratio 10:3 was selected as an optimized for-
mulation with 7.4 ± 0.3kg/cm2 hardness, 0.27 ± 0.11%
friability, and 24 hrs drug release proﬁle (Figure 2). This
formulation exhibit nearly zero-order release proﬁle with
(n = 0.933) in dissolution medium. As shown in Table 4,i n
all the three batches of these tablets no signiﬁcant diﬀerence
(P<0.05)wasobservedwithrespecttodrugcontent.Several
parameters were evaluated for the stability study including
hardness,friability,drugcontent,weightvariation,andphys-
ical appearance showing no signiﬁcant diﬀerence at accel-
erated storage conditions (40◦C ± 2&7 5± 5% RH) after
storage for 1, 2, 4, and 6 months.
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Figure 2: Comparative release proﬁles of ciproﬂoxacin HCl, a ref-
erence standard and test CR formulation (D:P ratio 10:3) in
phosphate buﬀer pH 7.4 (mean ± SEM, n = 6).
3.3. In Vivo Drug Performance. In vivo drug release perfor-
mance was done in rabbit serum by using high-performance
liquid chromatography. During in vivo study the rabbit se-
rum collected at zero time showed no peak while the serum
samples spiked with ciproﬂoxacin HCl showed single peaks
of the drug indicating that the adopted method was highly
selective.
The following Figures 3 and 4 shows the HPLC chro-
matograms of blank plasma and plasma sample of rabbit se-
rumafter4hrsoftestformulationadministrationcontaining
ciproﬂoxacin HCl. The retention time of ciproﬂoxacin HCl
was 3.30min with no interfering peak at the retention time
of ciproﬂoxacin HCl while the blank sample was clean.
The absolute recovery and retention time for ciproﬂox-
acin HCl was 95%. The coeﬃcient of determination (0.901)
showed a good level linearity of the method.
3.4. Pharmacokinetics of Ciproﬂoxacin HCl. Ciproﬂoxacin
HCl controlled release tablets showed signiﬁcantly diﬀerent
Tmax (8 ± 2.7hrs) as compared to Tmax of reference standard6 The Scientiﬁc World Journal
Table 4: Stability parameters of ciproﬂoxacin HCl CR tablets prepared at D:P ratio 10:3 (Mean ± SEM, n = 6).
Periods of sampling Hardness (kg) Friability (%) Appearance (colour) Drug content (%) Weight variation (%)
Before storage (0 time) 7.4 ±0.30 .27 ±0.11 White 103 ±24 ±0.3
After 1 month 7.2 ±0.40 .19 ±0.13 White 102 ±25 ±0.2
After 2 month 7.3 ±0.20 .27 ±0.13 White 103 ±35 ±0.4
After 4 month 7.1 ±0.40 .22 ±0.11 White 101 ±25 ±0.3
After 6 month 7.4 ±0.20 .24 ±0.12 White 102 ±34 ±0.2
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Figure 3: HPLC chromatogram of blank plasma.
(4 ± 1.2hrs), where P<0.05. Signiﬁcantly higher values of
peak time were observed. The half-life t1/2 of test CR for-
mulation was observed to be 18 ± 1.97hrs as compared to
reference conventional tablet 8 ± 0.78hrs, where P<0.05.
The higher values of Tmax and half-life t1/2 for test CR for-
mulations indicate the extended absorption phase and the
presence of drug for a long time in the body. Moreover, sig-
niﬁcantly optimized values of peak concentration (Cmax)
were observed for test CR tablets (44.7 ± 1.34ng/mL) as
compared to reference conventional formulation (78.32 ±
2.19ng/mL), where P<0.0001. Similarly, AUC0-t for test
formulation was 2251 ± 19ng·hr/mL as compared to re-
ference standard conventional formulation being 1962 ±
24ng·hr/mL and AUC0-∞ was 2157 ± 27ng·hr/mL and
2297 ± 21ng·hr/mL for test formulation and reference stan-
dard, respectively, which were not signiﬁcantly diﬀerent hav-
ing P<0.05. Nearly similar values of Cmax,A U C 0-t,a n d
AUC0-∞ indicate bioequivalence of the test CR formulations
to the reference standard conventional tablets.
3.5. In Vivo-In Vitro Correlation and Relative Bioavailability.
The test tablets were evaluated for relative bioavailability and
were found to 95% with a signiﬁcant extended absorption
phase.
As shown in Figure 6, by plotting the percent drug re-
leased (in vitro) against percent drug absorbed (in vivo) the
value of R2 was 0.934 indicating a good in vivo-in vitro cor-
relation.
4. Discussions
During in vitro dissolution studies, it was observed that as
compared to reference standard, the drug release patterns of
all the test formulations extend to a longer time but most
optimized was the formulation prepared at D:P ratio 10:3.
During the in vitro dissolution, a common phenomenon of
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Figure 4: HPLC chromatogram of sample obtained from rabbit
serum at 4 hours after drug administration.
tablet swelling was observed which might be due to the hy-
dration of the polymer. This swelling leads to rapid decrease
in glass transition temperature (Tg) of the polymer to the
temperature of the dissolution solvent. The dissolution sol-
vent exerts a stress on the polymer due to which a relaxation
response occurs in polymer chains which increase the dis-
tance among the polymer chains leading to swelling of the
tablet [14]. Moreover, due to hydration the volume of poly-
mer increases which reduce the free volume because of the
formation of microspores which itself acts as a shift in drug
transport mechanisms [15]. From the in vitro drug release
proﬁles it could be observed that the release was highly de-
pendent on polymer concentration, as the amount of poly-
mer was increased more extended release proﬁles were ob-
tained and a linear curve was obtained shifting the drug
transport mechanism to nearly zero order or zero-order re-
leasekinetics.Thereductionindrugreleaseratesandextend-
ed release proﬁles by increasing the polymer concentration
may be due to slow hydration of the matrix material depend-
ing upon the hydrophobic character of ETHOCEL [9]. It is
suggested that on dehydration the matrix material swallows
and enclosed the drug thus allowing a small amount of drug
in certain time through small microspores of the swollen
tablet [4, 15]. Similar results were found while studying the
eﬀect of polymers on in vitro drug release proﬁles of ibupro-
fen,wheretheincreaseinconcentrationofpolymerdecreases
the drug release and exhibit extended drug release proﬁles
[16]. The selection of ETHOCEL was based on the fact that
ETHOCEL is a hydrophobic polymer so is not signiﬁcantly
aﬀected by the variable pH of the GIT thus could give cipro-
ﬂoxacin release from the polymeric tablet irrespective of the
change of pH of GIT [17].
Drug release mechanism from ciproﬂoxacin controlled
release dosage forms was elucidated by ﬁtting the in vitro
dissolution data in Korsmeyer-Peppas equation which bestThe Scientiﬁc World Journal 7
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Figure 5: Comparative plasma concentrations versus time proﬁles
of ciproﬂoxacin HCl test tablets and reference standard conven-
tional tablets (mean ± SEM, n = 6).
describes the drug transport mechanism where the value of
diﬀusion coeﬃcient “n” was calculated through the slope
of the straight line of the data. The value of “n” for the
optimized formulation was greater than 0.5 and lesser than 1
(1 >n>0.5) indicating nearly zero-order, anomalous, or
non-Fickian case II transport mechanism, where Fickian is
drug transport through pores of tablet matrix, zero order
indicates a drug transport mechanism through the erosion
of polymer chains, and anomalous demonstrates the drug
transport mechanism through a combined eﬀect of diﬀusion
and erosion [9]. The linearity of the regression line was de-
termined by coeﬃcient of determination R2 the value of
which was nearly 1.
In the presented study, animal models were used to
study the in vivo performance of ciproﬂoxacin HCl which
showed that the developed CR formulations maintain a
constant blood plasma level for approximately long period
of time as compared to a reference conventional dosage form
which gain a rapid peak plasma concentration but could not
maintain it. The extended half-life t1/2 and the time which
is required to achieve peak plasma concentration Tmax were
representative of a slower drug release rate and an extended
time period. The AUCs of both the test and reference formu-
lationswerenotsigniﬁcantlydiﬀerentindicatingthatthefor-
mulations were bioequivalent. ETHOCEL were found a sig-
niﬁcant rate controlling polymer which can produce tablets
of desired hardness and friability giving a nearly zero-order
drug release and maintaining a nearly constant peak plasma
level in desired therapeutic rang thus minimizing the risk
of reaching drug plasma concentrations above MTC (max-
imum toxic concentration), therefore, avoiding drug toxicity
and side eﬀects and improves tolerability and adherence [9].
The plasma serum concentration of ciproﬂoxacin HCl
versus time proﬁle from reference conventional formulation
and test formulation could be seen from the Figure 5 given
y = 0.976x+12.16
R2 = 0.934
In vivo-in vitro correlation of ciproﬂoxacin
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Figure 6: Percent drug released (Pr) plotted against percent drug
absorbed (Pa) of ciproﬂoxacin HCl.
above. It could be seen that plasma concentrations of cipro-
ﬂoxacin were detectable even at 60hr. A gradual increase
in serum concentration was observed reaching the peak
plasma concentration at about 8hrs after drug administra-
tion via oral route and maintained for about 20hrs reﬂecting
a controlled release formulation. It was observed that the re-
ferenceformulationhadahigherandfasterpeakplasmacon-
centration in short time as compared to test CR formulation
indicating a slow and steady rate of drug absorption from the
CRtestformulation.Asimilarresultwasfoundbyinvestigat-
ing Olanzapine in rabbit serum after administering a test CR
formulation and a reference conventional formulation [9].
Ciproﬂoxacin HCl controlled release matrix tablets were
also evaluated for relative bioavailability and was found to be
95% indicating 95% relative bioavailability for both the test
formulation and reference formulation but the test formula-
tion having a stable and constant peak plasma concentration
for an extended period of time as compared to the reference
conventional dosage form.
A good understanding of in vivo-in vitro (IVIVC) corre-
lation being the major objective in preparations of phar-
maceutical dosage forms. Dissolution speciﬁcations can be
established using IVIVCs and can be used for the validation
of these dissolution speciﬁcations. IVIVCs are widely prac-
ticed in the development of oral controlled release/sustain
release dosage forms. For in vivo-in vitro correlation, the
value of coeﬃcient determination R2 (0.934) indicating a
good correlation between in vitro drug release and in vivo
drug absorption.
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